6,399 press releases indexed under healthcare.
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
Geneva, Switzerland, Aug. 26, 2026 (GLOBE NEWSWIRE) -- QASIC initially targets the cybersecurity, medical and automotive sectors by combining SEALSQ’s post-quantum security technologies with IC’Alps’ advanced custom-chip design capabilities
ConV2X today announced a new group of in-person speakers joining its September 24–25 executive summit at The Foundry in Cambridge, Massachusetts, expanding the multidisciplinary dialogue around AI infrastructure, decentralized health, cybersecurity, regulation, clinical implementation and the technologies reshaping healthcare and life sciences. - - The newly announced in-person participants bring experience from healthcare delivery, FDA leadership and regulation, enterprise AI, cybersecurit... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359477
(PR-inside.com) The corrected official transcripts are now public. FDA's supervising scientist named who directed the change in standard: the Assistant Secretary for Health - the same office that produced the government's headline evidence and never sent a witness. WASHINGTON, D.C. / ACCESS Newswire / August 26, 2026 / The Drug Enforcement Administration has released the corrected official transcripts from all 11 days of its marijuana-rescheduling hearing. MMJ International Holdings, Inc. ("MMJ") has reviewed them against the Government's 50-page closing brief. Buried inside thousands of pages is one admission that cuts through nearly every political argument surrounding Schedule III: Marijuana would not have passed ..
The corrected official transcripts are now public. FDA's supervising scientist named who directed the change in standard: the Assistant Secretary for Health - the same office that produced the government's headline evidence and never sent a witness.
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:
CHICAGO, August 26, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.
Tate & Lyle PLC ('Tate & Lyle'), a global leader in ingredient solutions for healthier food and beverages, has set an ambitious new target to fill consumer's daily 'fibre gap' by delivering an additional 15g of fibre per day to people's diets, 35 billion times by 2030. This fibre fortification goal has been added to Tate & Lyle's 2030 purpose targets. - - The recommended global intake of fibre is around 30g each day. However, the average global daily adult intake falls well short of this by... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=359508
NEW YORK, August 26, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events:
TOKYO, August 26, 2026--The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoa
First-of-its-kind study shows sustained Zepbound use in older adults with obesity lowers costs, reinforcing the potential value of the Medicare GLP-1 Bridge program Individuals treated with Zepbound had lower rates of hospital admissions and emergency department visits INDIANAPOLIS, Aug....
CAMBRIDGE, Mass., Aug. 26, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of US$106....